EN

What the GLP‑1 trials found

Pick a medicine and dose to see its main trial as the FDA label reports it: average weight change, how many people reached 5, 10, 15 or 20%, and the side effects and stopping rates beside them.

Nothing you enter leaves your device Every number cites its label section
Trial averages, not a prediction for you. This doesn't replace the label or your prescriber. Some people lose much more than the average and some lose very little. Talk to your prescriber before starting, stopping or changing a medicine.Information only, not a promotion. Every medicine named here is prescription-only. Only a prescriber can decide whether one is right for you and prescribe it. We don't recommend, rank or favor any medicine. Where we list several, they're in alphabetical order. We don't sell medicines or take money from drug companies.

Pick a medicine and dose

Medicine
lb

Shows what the trial's averages and proportions would mean in pounds. Not a prediction.

How these trials work
  • People were put into groups by chance: one got the medicine, one got a placebo (a dummy injection or dummy pill with no medicine in it).
  • Both groups got the same diet and activity advice.
  • The gap between the two groups is what the medicine added.
These trials can't be ranked against each other. They had different people, lengths, doses and diet advice, and ran at different times. Only a head-to-head trial tests two medicines in the same trial: see Compare.

Private by design: worked out in your browser. Nothing is sent or stored, and nothing goes in the link. Privacy notice

How this works

For each medicine we use the main trial in its FDA label (the official prescribing information), section 14 ("Clinical studies"). Side effects and stopping rates come from section 6.1, which often pools several trials; the card says which. Where the label doesn't give a number for that trial alone, we use the published trial paper and say so. Every number sits in one data block on this page with its source.

"Mean" weight change is the average for the whole group. The share who reached at least 5, 10, 15 or 20% shows the spread: it's a range, not one number. If you enter your weight, we multiply it by the same percentages. That's arithmetic on trial averages, not a forecast.

Ozempic, Mounjaro and Rybelsus are approved for type 2 diabetes, not weight loss. Their labels report weight change from diabetes trials in kilograms only, so we show that and nothing more.

What this can't tell you

  • How much you will lose. Your result depends on you, your dose and how long you take it, and isn't predicted by a trial average.
  • Which medicine works more. Separate trials can't be ranked.
  • What happens after stopping. Weight usually comes back in part: see Stopping and the long term.
  • Rare or long-term risks. Those are in each label's warnings, and in Side effects and risks.

Questions people ask

Can I compare the numbers for different medicines?

No. Each trial had different people, lengths, doses and diet advice, so the numbers can't be ranked against each other. Only a head-to-head trial, where both medicines are tested in the same trial, can compare them.

Is this how much weight I will lose?

No. These are trial averages, not a prediction for you. In every trial some people lost much more than the average and some lost very little. That's why the tool shows how many people reached each amount, not one number.

What is a placebo?

A dummy injection or dummy pill with no medicine in it. In these trials people were put into groups by chance, and both groups got the same diet and activity advice. The gap between the medicine group and the dummy group is what the medicine added.

Why are Ozempic, Mounjaro and Rybelsus shown differently?

They're approved for type 2 diabetes, not weight loss. Their labels report weight change from diabetes trials in kilograms, and not how many people lost 5% or more, so the tool shows only the average change for them.

Is anything I enter saved or sent?

No. The weight you enter is used only in your browser to turn the trial percentages into pounds. Nothing is sent or stored.

Sources

  1. Wegovy (semaglutide) injection and tablets, US prescribing information, Novo Nordisk, revised 06/2026. Section 14.2 (Table 8: Study 2 = STEP 1; Table 11: Study 7 = OASIS 4; Table 12: Study 8 = STEP UP; stopping rates in the Results text) and 6.1 (Tables 3 and 4). Maker's PDF · DailyMed. Checked Oct 14, 2026.
  2. Zepbound (tirzepatide) injection, US prescribing information, Eli Lilly, revised 8/2026. Section 14.1 (Table 2: Study 1 = SURMOUNT-1) and 6.1 (Table 1, Studies 1 and 2 pooled). Maker's PDF · DailyMed. Checked Oct 14, 2026.
  3. Saxenda (liraglutide) injection, US prescribing information, Novo Nordisk, revised 02/2026. Section 14.1 (Table 4: Study 1 = SCALE Obesity and Prediabetes; stopping rates in the text) and 6.1 (Table 2). Maker's PDF · DailyMed. Checked Oct 14, 2026.
  4. Foundayo (orforglipron) tablets, US prescribing information, Eli Lilly, revised 7/2026. Section 14 (Table 6: Trial 1 = ATTAIN-1, NCT05869903) and 6.1 (Table 1, Trials 1 and 2 pooled). Maker's PDF · DailyMed. Checked Oct 14, 2026.
  5. Ozempic (semaglutide) injection, US prescribing information, Novo Nordisk, revised 05/2026. Section 14.1 (monotherapy trial NCT02054897 = SUSTAIN 1, Table 3 and text) and 6.1 (Table 1 and gastrointestinal text). Maker's PDF · DailyMed. Checked Oct 14, 2026.
  6. Mounjaro (tirzepatide) injection, US prescribing information, Eli Lilly, revised 8/2026. Section 14.2 (Table 4: SURPASS-1) and 6.1 (Table 1, SURPASS-1 and -5 pooled, and gastrointestinal text). Maker's PDF · DailyMed. Checked Oct 14, 2026.
  7. Rybelsus and Ozempic (semaglutide) tablets, US prescribing information, Novo Nordisk, revised 1/2026. Section 14.2 (Trial 1 = PIONEER 1, NCT02906930, text under Table 4) and 6.1 (Table 2 and gastrointestinal text). Maker's PDF · DailyMed. Checked Oct 14, 2026.
  8. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. PMID 35658024. Abstract: stopping because of adverse events 4.3%, 7.1%, 6.2% and 2.6%. Funded by Eli Lilly. PubMed. Checked Oct 14, 2026.
  9. Wharton S et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med 2025. PMID 40934115. Abstract: gastrointestinal adverse events 74.0% vs 42.2%. Funded by Novo Nordisk. PubMed. Checked Oct 14, 2026.
  10. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. PMID 33567185. Funded by Novo Nordisk. PubMed. Checked Oct 14, 2026.
  11. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol 2025. PMID 40961952. Funded by Novo Nordisk. PubMed. Checked Oct 14, 2026.
  12. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med 2025. PMID 40960239. Doses 6, 12 and 36 mg of the investigational form. Funded by Eli Lilly. PubMed. Checked Oct 14, 2026.
  13. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE Obesity and Prediabetes). N Engl J Med 2015;373:11-22. PMID 26132939. Funded by Novo Nordisk. PubMed. Checked Oct 14, 2026.

Last checked Oct 14, 2026 · Next review due Jan 14, 2027

How this tool was made. Written by the GLP Guidebook team from the US labels and trial papers above, each opened and checked. The trials were paid for by the makers of the medicines (Novo Nordisk or Eli Lilly). It's general information, not medical advice, and it doesn't replace the label or your prescriber. Talk to your doctor or another licensed prescriber before starting, stopping or changing any medicine. How we write